A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.

Authors :: Kumar A
Blum KA
Fung HC
Smith MR
Foster PA
Younes A
Source :: British journal of haematology [Br J Haematol] 2015 Mar; Vol. 168 (6), pp. 902-4. Date of Electronic Publication: 2014 Oct 01.
Publication Year :: 2015

Subjects :: Adult
Antibodies, Monoclonal, Humanized administration & dosage
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Recurrence
Young Adult
Antineoplastic Agents administration & dosage
Hodgkin Disease drug therapy

Full Text Access

Tools